MA41375A - Anticorps igg bispécifiques et leurs procédés de préparation - Google Patents

Anticorps igg bispécifiques et leurs procédés de préparation

Info

Publication number
MA41375A
MA41375A MA041375A MA41375A MA41375A MA 41375 A MA41375 A MA 41375A MA 041375 A MA041375 A MA 041375A MA 41375 A MA41375 A MA 41375A MA 41375 A MA41375 A MA 41375A
Authority
MA
Morocco
Prior art keywords
igg antibodies
preparation processes
bispecific igg
bispecific
processes
Prior art date
Application number
MA041375A
Other languages
English (en)
Inventor
Hector Aldaz
Shane Atwell
Stephen J Demarest
Karen J Froning
Brian Arthur Kuhlman
Andrew Philip Leaver-Fay
Original Assignee
Lilly Co Eli
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Univ North Carolina Chapel Hill filed Critical Lilly Co Eli
Publication of MA41375A publication Critical patent/MA41375A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA041375A 2015-01-22 2016-01-20 Anticorps igg bispécifiques et leurs procédés de préparation MA41375A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562106494P 2015-01-22 2015-01-22

Publications (1)

Publication Number Publication Date
MA41375A true MA41375A (fr) 2017-11-28

Family

ID=55358122

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041375A MA41375A (fr) 2015-01-22 2016-01-20 Anticorps igg bispécifiques et leurs procédés de préparation

Country Status (5)

Country Link
US (2) US10774156B2 (fr)
EP (1) EP3247721B1 (fr)
ES (1) ES3031036T3 (fr)
MA (1) MA41375A (fr)
WO (1) WO2016118742A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014150973A1 (fr) * 2013-03-15 2014-09-25 Eli Lilly And Company Procédés de production de fab et d'anticorps bispécifiques
US20190241878A1 (en) 2016-07-01 2019-08-08 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
WO2018118616A1 (fr) 2016-12-22 2018-06-28 Eli Lilly And Company Procédés de production d'anticorps bispécifiques fabs et igg
EP3589650A1 (fr) 2017-03-02 2020-01-08 Novartis AG Protéines hétérodimères modifiées
CN110869394A (zh) 2017-06-16 2020-03-06 伊莱利利公司 工程改造的抗体化合物及其缀合物
CA3073537A1 (fr) 2017-08-22 2019-02-28 Sanabio, Llc Recepteurs d'interferon solubles et leurs utilisations
AU2018387829B2 (en) 2017-12-22 2024-12-19 Argenx Bvba Bispecific antigen binding construct
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
US20240132626A1 (en) * 2018-04-13 2024-04-25 Eli Lilly And Company Fab-Based Trispecific Antibodies
TWI722535B (zh) 2018-08-21 2021-03-21 美商美國禮來大藥廠 測定蛋白質或肽濃度的方法及其用途
US20220176011A1 (en) * 2019-02-18 2022-06-09 Lankenau Institute For Medical Research Scar reducing wound closure materials
BR112021022405A2 (pt) * 2019-05-09 2022-04-19 Merus Nv Domínios variantes para multimerização de proteínas e separação das mesmas
CA3149939A1 (fr) 2019-09-06 2021-03-11 Stephen J. Demarest Proteines comprenant des domaines constants de recepteur de lymphocytes t
CA3173162A1 (fr) 2020-03-25 2021-09-30 Eli Lilly And Company Proteines de liaison multispecifiques et leurs procedes de developpement
CA3204625A1 (fr) * 2021-01-11 2022-07-14 Caitlin STEIN Domaines ch3 variants modifies pour une heterodimerisation ch3 preferentielle, anticorps multi-specifiques les comprenant, et leurs procedes de fabrication
CN114106192B (zh) * 2021-12-20 2024-06-14 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用
US20250064958A1 (en) 2023-08-22 2025-02-27 Eli Lilly And Company AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENTS
WO2025085352A1 (fr) 2023-10-18 2025-04-24 Eli Lilly And Company Protéines de liaison au récepteur de la transferrine et leurs utilisations
WO2025166111A1 (fr) 2024-02-02 2025-08-07 Eli Lilly And Company Conjugués comportant une protéine de liaison au récepteur de la transferrine
WO2025166107A1 (fr) 2024-02-02 2025-08-07 Eli Lilly And Company Agents arni de sarm1 ciblant le snc
WO2025224084A1 (fr) 2024-04-22 2025-10-30 Engimmune Therapeutics Ag Protéines comprenant des domaines constants du récepteur des lymphocytes t
WO2025250605A1 (fr) 2024-05-31 2025-12-04 Eli Lilly And Company Agents d'interférence d'arn acvr2a et acvr2b

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US573168A (en) 1896-12-15 silberman
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
ME01803B (fr) 2004-08-05 2010-12-31 Genentech Inc Antagonistes anti-cmet humanises
EP3050963B1 (fr) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
AU2007227292B2 (en) 2006-03-17 2012-04-12 Biogen Ma Inc. Stabilized polypeptide compositions
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
ES2667863T3 (es) 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
US8802089B2 (en) * 2008-01-03 2014-08-12 Genmab A/S Monoclonal antibodies against CD32B
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2580243B1 (fr) * 2010-06-09 2019-10-16 Genmab A/S Anticorps dirigés contre le cd38 humain
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
EA201791693A1 (ru) 2011-03-25 2018-05-31 Гленмарк Фармасьютикалс С.А. Гетеродимерные иммуноглобулины
CA2843158A1 (fr) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Anticorps bispecifiques a fc en tandem
EP2773671B1 (fr) * 2011-11-04 2021-09-15 Zymeworks Inc. Structure d'anticorps hétérodimérique stable comprenant des mutations dans le domaine fc
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2014150973A1 (fr) 2013-03-15 2014-09-25 Eli Lilly And Company Procédés de production de fab et d'anticorps bispécifiques
TW201517916A (zh) 2013-03-15 2015-05-16 Lilly Co Eli Ｖｅｇｆｒ１抗體之治療用途
WO2014154254A1 (fr) 2013-03-26 2014-10-02 Nokia Solutions And Networks Oy Méthode et appareil
CN106573986A (zh) * 2014-07-29 2017-04-19 豪夫迈·罗氏有限公司 多特异性抗体
JP7239320B2 (ja) * 2015-10-02 2023-03-14 エフ． ホフマン－ラ ロシュ アーゲー 多重特異性抗体
WO2018118616A1 (fr) * 2016-12-22 2018-06-28 Eli Lilly And Company Procédés de production d'anticorps bispécifiques fabs et igg
EP3589650A1 (fr) * 2017-03-02 2020-01-08 Novartis AG Protéines hétérodimères modifiées
AR112341A1 (es) * 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
US20240132626A1 (en) * 2018-04-13 2024-04-25 Eli Lilly And Company Fab-Based Trispecific Antibodies

Also Published As

Publication number Publication date
EP3247721A1 (fr) 2017-11-29
WO2016118742A1 (fr) 2016-07-28
US20180009908A1 (en) 2018-01-11
US20210054103A1 (en) 2021-02-25
ES3031036T3 (en) 2025-07-03
US11976136B2 (en) 2024-05-07
EP3247721B1 (fr) 2025-05-07
US10774156B2 (en) 2020-09-15

Similar Documents

Publication Publication Date Title
MA41375A (fr) Anticorps igg bispécifiques et leurs procédés de préparation
FR25C1020I1 (fr) Anticorps thérapeutiques et leurs utilisations
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
FR25C1022I1 (fr) Anticorps anti-pd-1
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
EP3389699A4 (fr) Anticorps monoclonaux chimériques et humanisés anti-ctla4 humaine, et leurs utilisations
MA43955A (fr) Anticorps anti-bcma et anti-cd3 bispécifiques de format bite
EP3377102C0 (fr) Anticorps anti-pd-1 et leurs utilisations thérapeutiques
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
EP3334824A4 (fr) Anticorps anti-pd-1
EP3426686A4 (fr) Anticorps anti-pacap humanisés et leurs utilisations
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
EP3387442A4 (fr) Anticorps anti-cd73 humanisés
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
MA42626A (fr) Nouveaux anticorps anti-pd-1
EP3316909A4 (fr) Anticorps anti-ntb-a ainsi que compositions et procédés associés
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
EP3363816A4 (fr) Anticorps anti-ox40 et son application
EP3397276A4 (fr) Anticorps et conjugués de ceux-ci
EP3441086A4 (fr) Anticorps monoclonal anti-pd-1
EP3383904A4 (fr) Anticorps ctla-4 et leurs utilisations